Every treatment that has ever made a difference in cancer care was once a part of a clinical trial. MUSC Hollings Cancer Center is committed to offering the best treatments available today while searching for even better ones for the future. Ask your doctor if a clinical trial is right for you.
STUDY17022 First in Human, Phase 1/1b, Open label, Multicenter Study of Bifunctional EGFR/TGF ß Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients with EGFR Driven Advanced Solid Tumors The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors. Study Information
STUDY21565 A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor (Endometrial cohort enrolling 2nd and 3rd line patients.) To assess safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s). To assess pharmacokinetic (PK) profile of study drug(s) To assess efficacy (objective response rate [ORR], best overall response [BOR], disease control rate [DCR], clinical benefit rate [CBR], progression-free survival [PFS], overall survival [OS], and duration of response [DOR]) of E7386 in combination with other anticancer drug(s) (Revised per Amendment 06) Study Information
STUDY24160 An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Dose-Expansion, Phase 1/2 Study of BBI-355 and BBI-355 in Combination with Select Targeted Therapies in Subjects with Locally Advanced or Metastatic Solid Tumors with Oncogene Amplifications To assess the safety, tolerability, and dose-limiting toxicities (DLTs) of BBI-355 as a single agent administered orally at escalating dose levels in adult subjects with locally advanced or metastatic solid tumors with oncogene amplifications. To assess the safety, tolerability, and DLTs ofBBI-355 in combination with each of the following agents: erlotinib, futibatinib, or abemaciclib, at escalating dose levels in adults with locally advanced or metastatic solid tumors with corresponding oncogene amplifications. To determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) of BBI-355 as a single agent. To determine the MTD and the RP2D of BBI-355 in combination with each of the following agents: erlotinib, futibatinib, or abemaciclib. Study Information
STUDY25167 A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas To assess whether the combination of doxorubicin and pembrolizumab will improve progression free survival in UPS and related poorly differentiated sarcomas relative to doxorubicin alone. Study Information